ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Century Therapeutics Inc

Century Therapeutics Inc (IPSC)

0.6935
-0.0085
(-1.21%)
마감 27 2월 6:00AM
0.6726
-0.0209
( -3.01% )
시간외 단일가: 9:32PM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
0.6726
매수가
0.6703
매도가
0.77
거래량
456
0.00 일간 변동폭 0.00
0.66 52주 범위 5.51
market_cap
전일 종가
0.6935
개장가
-
최근 거래 시간
100
@
0.6726
(formt)
마지막 거래 시간
20:04:29
재정 규모
-
VWAP
-
평균 볼륨(3m)
569,829
발행 주식
85,029,042
배당수익률
-
주가수익률
-0.43
주당순이익(EPS)
-1.61
매출
2.24M
순이익
-136.67M

Century Therapeutics Inc 정보

Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a plays a central role in the production of blood cells in the bone marrow. It is assembling a portfoli... Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a plays a central role in the production of blood cells in the bone marrow. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Century Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker IPSC. The last closing price for Century Therapeutics was US$0.69. Over the last year, Century Therapeutics shares have traded in a share price range of US$ 0.66 to US$ 5.51.

Century Therapeutics currently has 85,029,042 shares in issue. The market capitalisation of Century Therapeutics is US$58.97 million. Century Therapeutics has a price to earnings ratio (PE ratio) of -0.43.

IPSC 최신 뉴스

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.1195-15.08647897990.79210.81910.665815870.72362146CS
4-0.1516-18.39359378790.82420.88980.664710650.76082466CS
12-0.7374-52.29787234041.411.740.665698291.00744598CS
26-1.3174-66.20100502511.992.020.664959941.24024462CS
52-2.8974-81.15966386553.575.510.663426181.68532158CS
156-12.5274-94.904545454513.215.3750.662061223.43687255CS
260-18.8274-96.550769230819.532.8990.661994796.52890976CS

IPSC - Frequently Asked Questions (FAQ)

What is the current Century Therapeutics share price?
The current share price of Century Therapeutics is US$ 0.6726
How many Century Therapeutics shares are in issue?
Century Therapeutics has 85,029,042 shares in issue
What is the market cap of Century Therapeutics?
The market capitalisation of Century Therapeutics is USD 58.97M
What is the 1 year trading range for Century Therapeutics share price?
Century Therapeutics has traded in the range of US$ 0.66 to US$ 5.51 during the past year
What is the PE ratio of Century Therapeutics?
The price to earnings ratio of Century Therapeutics is -0.43
What is the cash to sales ratio of Century Therapeutics?
The cash to sales ratio of Century Therapeutics is 26.24
What is the reporting currency for Century Therapeutics?
Century Therapeutics reports financial results in USD
What is the latest annual turnover for Century Therapeutics?
The latest annual turnover of Century Therapeutics is USD 2.24M
What is the latest annual profit for Century Therapeutics?
The latest annual profit of Century Therapeutics is USD -136.67M
What is the registered address of Century Therapeutics?
The registered address for Century Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Century Therapeutics website address?
The website address for Century Therapeutics is www.centurytx.com
Which industry sector does Century Therapeutics operate in?
Century Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ULYUrgent ly Inc
US$ 0.7331
(74.55%)
24.19M
ANNAAleAnna Inc
US$ 11.31
(59.97%)
10
NIXXNixxy Inc
US$ 2.37
(50.00%)
22.34M
XNETXunlei Ltd
US$ 4.23
(45.86%)
4.98M
MNPRMonopar Therapeutics Inc
US$ 42.88
(37.04%)
253
TOIIWOncology Institute Inc
US$ 0.0186
(-54.52%)
2
UVSPUnivest Financial Corporation
US$ 21.17
(-29.34%)
6
SYTASiyata Mobile Inc
US$ 3.03
(-27.34%)
121.09k
SPGCSacks Parente Golf Inc
US$ 0.535
(-26.92%)
583.46k
DMRCDigimarc Corporation
US$ 20.00
(-26.04%)
31.05k
ULYUrgent ly Inc
US$ 0.7331
(74.55%)
24.19M
NIXXNixxy Inc
US$ 2.37
(50.00%)
22.34M
VMARVision Marine Technologies Inc
US$ 0.917
(25.44%)
16.1M
ICCTiCoreConnect Inc
US$ 1.31
(20.18%)
15.24M
CPOPPop Culture Group Company Ltd
US$ 0.9359
(35.25%)
10.75M

IPSC Discussion

게시물 보기
KIPK KIPK 1 주 전
LOL - jondoeuk & theoryslut!!! KARMIC Reflection....👀👀👀
👍️0
theorysuit theorysuit 2 주 전
do you have an lean between IPSC or FATE? Both look worth a lotto shot at discount to cash levels.
👍️0
glenn1919 glenn1919 2 월 전
ipsc..............................https://stockcharts.com/h-sc/ui?s=ipsc&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 월 전
IPSC, under $2
👍️0
glenn1919 glenn1919 3 월 전
IPSC......................https://stockcharts.com/h-sc/ui?s=IPSC&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 4 월 전
ASH abstracts

Successful Generation of iPSC-Derived CD4+ and CD8+ CAR T Cells with aß-like T Cell Function, Including Antigen-Dependent Expansion and IL-2 Production https://ash.confex.com/ash/2024/webprogram/Paper210428.html

Universal Cloaking of Allogeneic T Cell Therapies Against Natural Killer Cells Via CD300a Agonism https://ash.confex.com/ash/2024/webprogram/Paper211844.html

Optimizing Chimeric Antigen Receptor Endodomains for Effector Function and Cell Expansion in iPSC-Derived T-Cell Therapies https://ash.confex.com/ash/2024/webprogram/Paper210516.html

Leveraging Stage-Specific Promoters to Enhance Immune Cell Engineering in iPSC-Derived Cells for Cancer Immunotherapy https://ash.confex.com/ash/2024/webprogram/Paper210942.html

Natural Killer and ?d T Cells Derived from Engineered Induced Pluripotent Stem Cells Have Potent Preclinical Activity to Treat B Cell-Mediated Autoimmune Diseases https://ash.confex.com/ash/2024/webprogram/Paper210234.html
👍️0
TrendTrade2016 TrendTrade2016 4 월 전
WOUND TIGHT
👍️0
TrendTrade2016 TrendTrade2016 4 월 전
IPSC HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 4 월 전
ISPC RIGHT SYMBOL POST SPLIT
👍️0
jondoeuk jondoeuk 4 월 전
OT: First allo CAR-NK (data) https://acrabstracts.org/abstract/allogenic-cd19-car-nk-cells-therapy-in-refractory-systemic-lupus-erythematosus-an-open-label-single-arm-prospective-and-interventional-clinical-trial/
👍️0
Monksdream Monksdream 4 월 전
IPSC under $2
👍️0
jondoeuk jondoeuk 5 월 전
The new CSO founded Clade and served as its CEO. Dr. Cowan was a scientific founder of CRSP and founder and CSO of SANA as well https://finance.yahoo.com/news/century-therapeutics-strengthens-leadership-team-110000642.html
👍️0
Monksdream Monksdream 7 월 전
IPSC under $3
👍️0
jondoeuk jondoeuk 8 월 전
Something else Gadeta had been working on https://aacrjournals.org/cancerres/article/84/6_Supplement/3611/737213/Abstract-3611-A-patient-derived-organoid-platform
👍️0
jondoeuk jondoeuk 9 월 전
The single doses were nothing to write home about, and only one patient enrolled so far for the multiple doses https://www.globenewswire.com/news-release/2024/06/03/2892097/0/en/Century-Therapeutics-Presents-Interim-Results-from-Phase-1-ELiPSE-1-Study-at-ASCO-2024-Annual-Meeting.html

Poster https://www.centurytx.com/wp-content/uploads/20240517_Century_ASCO_FINAL.pdf
👍️0
jondoeuk jondoeuk 10 월 전
ASGCT PR https://finance.yahoo.com/news/century-therapeutics-presents-preclinical-data-110000872.html

The other poster

👍️0
jondoeuk jondoeuk 10 월 전
The poster

👍️0
jondoeuk jondoeuk 10 월 전
Preprint https://www.biorxiv.org/content/10.1101/2024.05.05.592600v1
👍️0
jondoeuk jondoeuk 11 월 전
Last year Clade Therapeutics announced the acquisition of Gadeta B.V. https://www.globenewswire.com/news-release/2023/10/02/2752753/0/en/Clade-Therapeutics-Announces-the-Acquisition-of-Gadeta-B-V.html

Gadeta was developing cell therapies expressing defined gamma-delta T-cell receptors that specifically recognise cancer cells. In order to harness the unique targeting properties of gamma-delta TCRs, Gadeta developed the TEG platform, which equips alpha-beta T-cells (used in the production of CAR and TCR therapies) with a defined gamma-delta TCR https://www.sciencedirect.com/science/article/pii/S0006497120448153

Gadeta also developed a novel proprietary gamma-delta TCR discovery engine based on a 'TCR centric' selection approach that sourced patient material (for a broad range of naturally selected gamma-delta TCRs from different tissues), screened (to identify tumour reactive gamma-delta TCRs from co-cultures of patient material) and selected gamma-delta TCRs optimal properties. Some preclinical data https://aacrjournals.org/cancerres/article/82/12_Supplement/2818/701504/Abstract-2818-Targeting-solid-tumors-with-GDT002-a
👍️0
jondoeuk jondoeuk 11 월 전
Upcoming (Fri, May 10) https://annualmeeting.asgct.org/program/agenda-speaker-details?agendaId=37279



As for the antibody degrader, I don't see them being able to combine the cells with therapeutic antibodies. But they might not need to add it.
👍️0
jondoeuk jondoeuk 11 월 전
Acquisition of Clade Therapeutics https://www.globenewswire.com/news-release/2024/04/11/2861378/0/en/Century-Therapeutics-Strengthens-Position-in-Autoimmune-Disease-with-Strategic-Pipeline-Expansion-Supported-by-60-Million-Private-Placement-and-Acquisition-of-Clade-Therapeutics.html

Some slides

👍️0
Monksdream Monksdream 11 월 전
IPSC under $5
👍️0
Lilman72003 Lilman72003 1 년 전
In 1.60
Out 4.35
👍️0
jondoeuk jondoeuk 1 년 전
Doesn't look that way with auto CAR-T. Out of the 15 treated, all had auto-antibodies, with 13 in skin, 11 in lung, 9 in kidney, 9 in joints, 4 in the heart, 3 in muscle, and other organs. Renal (kidney) disease occurs in up to 40% of patients and can evolve to kidney failure requiring dialysis and is associated with higher risk of death.

👍️0
NY1972 NY1972 1 년 전
CSO was smart selling off his shares. Depleting B cells is not investable, trading in SLE for B cell aplasia is a good deal?
👍️0
jondoeuk jondoeuk 1 년 전
Additional data https://century-therapeutics-initial-clinical-data-call.open-exchange.net/registration

Slides https://investors.centurytx.com/static-files/b88aac71-fffe-4b39-9573-82e3964f79b1
👍️0
jondoeuk jondoeuk 1 년 전
The PR https://www.biospace.com/article/releases/century-therapeutics-presents-initial-data-from-cnty-101-phase-1-elipse-1-trial-supporting-the-potential-for-a-multi-dosing-strategy-for-car-ink-enabled-by-allo-evasion-edits/

Poster https://www.centurytx.com/wp-content/uploads/2023-ASH-poster_Century-Tx_FINAL.pdf
👍️0
jondoeuk jondoeuk 1 년 전
Summary of the case that is going to be presented at ASH https://ash.confex.com/ash/2023/webprogram/Paper182313.html

Patient with high-risk R/R follicular lymphoma. Completed four 28-day cycles of CNTY-101 at the 100 million cell dose (DL1), first two administered following lymphodepletion, while the most recent two were administered without lymphodepletion. All doses of CNTY-101 with and without IL-2 or LD were well tolerated and demonstrated clinical benefit as defined as stable disease or better (per Lugano 2014 criteria). Responses were associated with tumour shrinkage and an ongoing CR of a duration of five months since the first CNTY-101 infusion. The PK data showed that CNTY-101 cells were detected after each infusion with comparable kinetics, with a limited duration in circulation. No measurable CDC-inducing functional ADA detected in any samples by data cut-off (including the first three cycles). Treatment was associated with changes in tumour microenvironment within eight days post-infusion, augmentation of adaptive T-cell responses, and tumour shrinkage.
👍️0
amateurtrader amateurtrader 2 년 전
CSO sold off his shares not sure why
👍️0
jondoeuk jondoeuk 2 년 전
Extensive epigenetic and transcriptomic donor-specific differences observed in iPSC derived allogenic NK (iNK) cells https://www.abstractsonline.com/pp8/#!/10828/presentation/6083

iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysis https://www.abstractsonline.com/pp8/#!/10828/presentation/3328
👍️0
jondoeuk jondoeuk 2 년 전
Link to the webcast https://century-therapeutics-virtual-research-development-day.open-exchange.net/registration
👍️0
jondoeuk jondoeuk 2 년 전
The company will host a virtual Research and Development Day on Friday, Nov 11, from 8:00 AM to 9:30 AM ET. The R&D Day will feature presentations from the management team and Jonathan Rosenberg, M.D., Chief of the Genitourinary Oncology Service at the Memorial Sloan Kettering Cancer Center, Physician at Memorial Hospital, and Professor of Medicine at Weill Cornell Medical College. The event will focus on the company's solid tumour strategy and gamma delta iT cell platform, including a discussion on preclinical data to be presented at the Society for Immunotherapy of Cancer Annual Meeting.
👍️0
jondoeuk jondoeuk 2 년 전
SITC titles

Empowering iPSC-Derived iNK Cells with Multiple Gene Edits to Improve Persistence and Anti-Tumor Efficacy

Multiple Targeting of Solid Tumors with iPSC-derived Gamma Delta CAR T Cells in Combination with Therapeutic Antibodies
👍️0
jondoeuk jondoeuk 2 년 전
Yes, and the expansion cohorts will include both CAR-T naïve and relapsed. Next data from them should be around Dec, so ASH or an investor event. They have decided not to go past 1.5B cells per dose (x three doses) for some reason. Based on the data so far there is a dose response relationship (300M or 1B per dose) and all CRs are ongoing.
👍️0
jondoeuk jondoeuk 2 년 전
They should. High-affinity CD16 variants in the population correlate with clinical outcomes, so better objective responses and progression-free survival. However, the CD16 receptor is cleaved from the surface of activated NK cells, which leads to dysfunction and reduced antibody-dependent cellular cytotoxicity.

FATE could present some early clinical data on both at FT538 and FT536 at SITC. The former is being tested in combo with mAbs, while the latter (has an added CAR, along with the same three edits* as the other) is as a single agent or with mAbs.

* https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(21)00350-7
👍️0
NY1972 NY1972 2 년 전
NKTX seems to repeat what DTIL tried with 19a/eLD. Why they don't increase the NK cells dose to 4 billions same as AUTO NK?
👍️0
NY1972 NY1972 2 년 전
Will the ISPC NK cells work if the mAb is the weakest link? .AFM24 v. cetuximab hold the key to success?

AZ just stopped the trial of monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
👍️0
jondoeuk jondoeuk 2 년 전
Looking at P1 data from Fate and NKTX, NK cells seem to be effective on indolent lymphoma and nodal DLBCL.

FATE and NKTX have other trials ongoing in certain haematological malignancy. Adoptive transfer can induce long-term and durable remissions after a haploidentical stem cell transplantation in R/R AML. In those that are unable to undergo transplantation across seven published studies (over one hundred patients in total), 34% achieved a complete response to NK cell therapy alone. However, it has been demonstrated that the absence of NKGD2 ligand expression on leukemic stem cells determines therapy resistance and immune escape. PARP1 inhibitors can induce expression of NKG2D ligands, so I would like to see certain combo therapies https://www.nature.com/articles/s41586-019-1410-1

For pts with high tumor burden or aggressive disease, CART will still be needed.

Even for CAR-T, intensive debulking chemo could help those with a high tumour burden https://www.frontiersin.org/articles/10.3389/fonc.2021.706087/full

I listened to NKTX presentation, the number of cycles given to a patient will be up to the oncologist.

In June, NKTX filed a protocol amendment with the FDA for the ongoing PhI trial of NKX019 to optimise the trial's design as the company prepares for potential dose expansion cohorts. The amended protocol, now in effect, allows for an increased dose of cyclophosphamide, in line with NKX101, and various expansion cohorts evaluating NKX019 in combination with rituximab. Also, three doses of CAR-NKs per cycle, with them currently enrolling a cohort testing 1.5 billion cells per dose.
👍️0
jondoeuk jondoeuk 2 년 전
According to a medical doctor on twitter they haven't been able to secure a source for the cbNKs. A second Fc receptor, CD64, binds to the same IgG's as CD16a, but with more than a 30-fold higher affinity. However, it is typically only expressed on myeloid cells, not NKs. FATE created a recombinant receptor consisting of the extracellular region of CD64 with transmembrane and intracellular regions of CD16a. Not only did they show activity, but additionally, the higher affinity of allowed for mAbs to be pre-adsorbed and improved targeting without additional mAb use. Also, they could still mix and match mAbs as well https://ashpublications.org/blood/article/136/Supplement%201/10/470430/Engineered-iPSC-Derived-NK-Cells-Expressing
👍️0
NY1972 NY1972 3 년 전
AFMD seemed to have solved the cleaved CD16 issue by pretreating the NK with their AFM13 ex-vivo.
👍️0
NY1972 NY1972 3 년 전
Looking at P1 data from Fate and NKTX, NK cells seem to be effective on indolent lymphoma and nodal DLBCL. For pts with high tumor burden or aggressive disease, CART will still be needed. I listened to NKTX presentation, the number of cycles given to a patient will be up to the oncologist.
👍️0
jondoeuk jondoeuk 3 년 전
Dr. Kaufman has presented some preclinical data

As for clinical, that comes from FATE and NKTX (using healthy donor), even though there are some differences between the programs in the same indications. From memory, in R/R NHL, FATE's best efficacy was achieved at a (much) lower dose (+/- rituximab), while NKTX had to go up to a billion across three doses (no rituximab).
👍️0
NY1972 NY1972 3 년 전
Has anyone compared ISPC NK to CBNK?
👍️0
jondoeuk jondoeuk 3 년 전
Slides https://investors.centurytx.com/static-files/f0d80de2-1e62-49b5-acfd-0e1388c58179
👍️0
jondoeuk jondoeuk 3 년 전
Link to webcast https://kvgo.com/corporate-services/century-therapeutics-rd-event
👍️0
jondoeuk jondoeuk 3 년 전
The poster https://www.centurytx.com/wp-content/uploads/2022/05/ASGCT22_Enabling-the-Engineering-of-iPSC-Based-Cell-Therapies-Using-MAD7-a-Novel-CRISPR-Nuclease.pdf
👍️0
jondoeuk jondoeuk 3 년 전
A virtual R&D update will be held on June 13, at 4:30 PM ET. Century's management will discuss CNTY-103 and progress on the next-generation platform. Dr Sheila Singh, Professor of Surgery and Biochemistry, Chief Paediatric Neurosurgeon at McMaster Children’s Hospital, the Division Head of Neurosurgery at Hamilton Health Sciences, and the inaugural Director of McMaster's new Cancer Research Centre will discuss the current treatment paradigm in GBM.
👍️0
jondoeuk jondoeuk 3 년 전
952: Enabling the Engineering of iPSC Based Cell Therapies Using MAD7, a Novel CRISPR Nuclease https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1867
👍️0
jondoeuk jondoeuk 3 년 전
ASGCT title:

Enabling the Engineering of iPSC Based Cell Therapies Using MAD7, a Novel CRISPR Nuclease.
👍️0
jondoeuk jondoeuk 3 년 전
Preclinical data on mbIL-15 https://ashpublications.org/blood/article/124/7/1081/33687/Autonomous-growth-and-increased-cytotoxicity-of

NKG2A https://www.jci.org/articles/view/123955

PET https://jnm.snmjournals.org/content/61/9/1348.long

As for allo evasion, it could be CD47 https://rupress.org/jem/article/218/3/e20200839/211668/The-SIRP-CD47-immune-checkpoint-in-NK-cellsSIRP

👍️0

최근 히스토리

Delayed Upgrade Clock